DCZ0415

Product NameDCZ0415
CAS2242470-43-3
MFC23H20N2O2
MW356.42
EINECS
MOL File2242470-43-3.mol

Chemical Properties

Boiling point	624.2±55.0 °C(Predicted)
Density	1.319±0.06 g/cm3(Predicted)
solubility	DMSO:62.5(Max Conc. mg/mL);175.35(Max Conc. mM)
form	Solid
pka	5.80±0.10(Predicted)
color	Off-white to yellow

Usage And Synthesis

Description

DCZ0415 is a novel inhibitor of TRIP13, suppressing multiple myeloma progression.

Uses

DCZ0415, a potent TRIP13 inhibitor, impairs nonhomologous end joining repair and inhibits NF-κB activity. DCZ0415 induces anti-myeloma activity in vitro, in vivo, and in primary cells derived from drug-resistant myeloma patients[1].

in vivo

DCZ0415 (ip; 50 mg/kg/day for 14 days) significantly reduces the growth of MM cells-induced tumors in immune-deficient mice^[1].

Animal Model:	Nude mice (6-weeks-old) with H929 775 cells^[1]
Dosage:	50 mg/kg
Administration:	Intraperitoneal injection; every day for 14 days
Result:	Significantly reduced the growth of MM cells-induced tumors.

target

DCZ0415, a potent TRIP13 inhibitor, impairs nonhomologous end joining repair and inhibits NF-κB activity.

IC 50

NF-κB

References

[1] Wang Y, et al. A Small Molecule Inhibitor Targeting TRIP13 suppresses multiple myeloma progression. Cancer Res. 2019 Nov 15. pii: canres.3987.2018. DOI:10.1158/0008-5472.CAN-18-3987